Kewalramani Reshma 4

What Happened
Reshma Kewalramani, CEO & President and a director of Vertex Pharmaceuticals (VRTX), sold a total of 40,000 shares in multiple open-market transactions on February 27, 2026. The lots ranged in price from about $479.75 to $497.17 and generated total proceeds of approximately $19,738,855 (weighted average ≈ $493.47 per share). These sales were made pursuant to Dr. Kewalramani’s company‑approved Rule 10b5-1 trading plan established on 11/17/2025, which typically allows scheduled sales regardless of short‑term views on the stock.

Key Details

• Transaction date: 2026-02-27 (reported on Form 4 filed 2026-03-03).
• Total sold: 40,000 shares for total proceeds of ~$19.74 million.
• Price range by lot: ~$479.75 to ~$497.17; overall weighted avg ≈ $493.47/share. (Footnotes F3–F15 list weighted averages and ranges for individual lines.)
• Plan: Sales executed under a 10b5-1 plan entered 11/17/2025 (Footnote F1). Dr. Kewalramani also agreed to provide detailed per-price share counts on request (Footnote F2).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing timeliness: No late‑filing flag shown in the provided data.

Context

• Sales conducted under an established 10b5-1 plan are generally considered routine, pre‑scheduled dispositions rather than a direct commentary on near‑term company prospects. Retail investors often focus more on insider purchases than on planned sales when assessing insider sentiment.
• The Form 4 only reports the disposition details; it does not explain the insider’s reasons (e.g., diversification, taxes, or personal liquidity).